Literature DB >> 14648662

Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma.

Raúl Cassia1, Gema Moreno-Bueno, Sandra Rodríguez-Perales, David Hardisson, Juan C Cigudosa, José Palacios.   

Abstract

Cyclin E overexpression occurs in a subset of endometrial carcinomas (ECs), but the molecular mechanisms underlying this alteration remain to be established. The present study has analysed amplification of the cyclin E gene (CCNE) and mutation in hCDC4, the gene coding for the F-box protein, which tags phosphorylated cyclin E for proteosomal degradation, to ascertain whether these alterations might be responsible for cyclin E overexpression in ECs. Cyclin E and p53 expression was studied by immunohistochemistry in eight atypical endometrial hyperplasias (AEHs), 51 endometrioid endometrial carcinomas (EECs), and 22 non-endometrioid endometrial carcinomas (NEECs). CCNE amplification was analysed by fluorescence in situ hybridization (FISH). Mutations in exons 2-11 of the hCDC4 gene were screened by PCR-SSCP-sequencing. Finally, the polymorphic marker D4S1610 was used to assess loss of heterozygosity (LOH) in the hCDC4 gene. Cyclin E overexpression was found in 26/81 (32%) cases and was associated with the histological type of the lesion, since it was not found in any AEHs but was present in 27% of EECs and 54.5% of NEECs (p=0.035). Cyclin E overexpression was associated with histological grade (p=0.011) and p53 immunostaining in EECs (p=0.033). CCNE amplification was found in 6 of 37 (16%) ECs examined. There was a significant association between CCNE amplification and the histological type of the lesion, since five (83%) of the six cases with amplification were NEECs (p=0.008). One EEC harboured an hCDC4 mutation: a CGA to CAA (Arg/Gln) change at codon 479. In addition, D4S1610 LOH was found in 7 of 23 (30%) informative cases analysed, but no correlation with cyclin E overexpression was found. However, the tumour with hCDC4 mutation also showed LOH. This is the first study demonstrating that cyclin E overexpression is associated with gene amplification in ECs, these alterations being more frequent in NEECs. Although hCDC4 exhibits a low mutation frequency in ECs overexpressing cyclin E, it seems to function as a tumour suppressor gene that is involved in endometrial carcinogenesis. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14648662     DOI: 10.1002/path.1474

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  16 in total

1.  FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein.

Authors:  Yan Song; Xinjia Zhou; Weiliang Bai; Xiulan Ma
Journal:  Tumour Biol       Date:  2015-01-14

Review 2.  Practical issues in the diagnosis of serous carcinoma of the endometrium.

Authors:  Sonia Gatius; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

3.  CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.

Authors:  Ayse Ayhan; Elisabetta Kuhn; Ren-Chin Wu; Hiroshi Ogawa; Asli Bahadirli-Talbott; Tsui-Lien Mao; Haruhiko Sugimura; Ie-Ming Shih; Tian-Li Wang
Journal:  Mod Pathol       Date:  2016-10-21       Impact factor: 7.842

4.  Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.

Authors:  Jingxiao Wang; Haichuan Wang; Michele Peters; Ning Ding; Silvia Ribback; Kirsten Utpatel; Antonio Cigliano; Frank Dombrowski; Meng Xu; Xinyan Chen; Xinhua Song; Li Che; Matthias Evert; Antonio Cossu; John Gordan; Yong Zeng; Xin Chen; Diego F Calvisi
Journal:  J Hepatol       Date:  2019-06-11       Impact factor: 25.083

Review 5.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

6.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

7.  In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.

Authors:  Mary Ellen Urick; Daphne W Bell
Journal:  Mol Carcinog       Date:  2018-07-12       Impact factor: 4.784

8.  FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.

Authors:  Roya Babaei-Jadidi; Ningning Li; Anas Saadeddin; Bradley Spencer-Dene; Anett Jandke; Belal Muhammad; ElSayed E Ibrahim; Ranjithmenon Muraleedharan; Mohammed Abuzinadah; Hayley Davis; Annabelle Lewis; Susan Watson; Axel Behrens; Ian Tomlinson; Abdolrahman Shams Nateri
Journal:  J Exp Med       Date:  2011-01-31       Impact factor: 14.307

9.  Predisposition to cancer caused by genetic and functional defects of mammalian Atad5.

Authors:  Daphne W Bell; Nilabja Sikdar; Kyoo-Young Lee; Jessica C Price; Raghunath Chatterjee; Hee-Dong Park; Jennifer Fox; Masamichi Ishiai; Meghan L Rudd; Lana M Pollock; Sarah K Fogoros; Hassan Mohamed; Christin L Hanigan; Suiyuan Zhang; Pedro Cruz; Gabriel Renaud; Nancy F Hansen; Praveen F Cherukuri; Bhavesh Borate; Kirk J McManus; Jan Stoepel; Payal Sipahimalani; Andrew K Godwin; Dennis C Sgroi; Maria J Merino; Gene Elliot; Abdel Elkahloun; Charles Vinson; Minoru Takata; James C Mullikin; Tyra G Wolfsberg; Philip Hieter; Dae-Sik Lim; Kyungjae Myung
Journal:  PLoS Genet       Date:  2011-08-25       Impact factor: 5.917

10.  Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.

Authors:  Matthieu Le Gallo; Andrea J O'Hara; Meghan L Rudd; Mary Ellen Urick; Nancy F Hansen; Nigel J O'Neil; Jessica C Price; Suiyuan Zhang; Bryant M England; Andrew K Godwin; Dennis C Sgroi; Philip Hieter; James C Mullikin; Maria J Merino; Daphne W Bell
Journal:  Nat Genet       Date:  2012-10-28       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.